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Abstract  
Background: Adverse Drug Reactions (ADRs) are a major public health problem. Prompt reporting of suspected ADRs is fundamental in 
the post-marketing surveillance of medicines and helps in ensuring medicine safety. However, fewer ADRs are reported in general and 
in particular by community pharmacists. There is limited knowledge about the factors which are preventing community pharmacists in 
the UK from reporting an ADR. 
Objectives: To identify the barriers to ADR reporting among community pharmacists practicing in the UK. 
Methods: A cross sectional study using a 25-items questionnaire (both online and paper based) including 10 barriers to ADR reporting 
was conducted from 1st April 2012 to September 2012. Community pharmacists practicing in the West Midlands, UK, were 
approached for the participation in this study. Chi-Square and regression were applied to identify covariates for the barriers to ADR 
reporting. A significant value of 0.05 was assigned for analysis. 
Results: Of the 230 invited community pharmacists, 138 pharmacists responded (response rate 60%). The median age of respondents 
was 31 years. All pharmacists reported that they would report both serious and mild ADRs from drugs with black triangle among 
children as well as adults. About 95% (n=131) of the pharmacists were familiar with the paper based ADR reporting system. Store-
based pharmacists were more likely to be more confident about which ADRs to report [0.680, 95% Confidence Interval 0.43-3.59]. Lack 
of time 46.4% (n=64), and pharmacists perception that ADR is not serious enough to report (65.2%; n=90) were identified as barriers to 
ADR reporting. Majority 63.0% (n=87) of the pharmacists identified training and information about what to report and access to 
Information Technology (IT) (For example access to internet connection) 61.6% (n=85) as facilitators to ADR reporting process. 
Conclusion: Lack of time and ADRs considered not serious enough by pharmacists to report were barriers to ADR reporting. Further 
training and education about the types of ADRs to be reported can help to improve the reporting of ADRs. 
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INTRODUCTION 
Adverse Drug Reactions (ADRs) are a major public health 
problem and are a known cause for prolonged hospital stay 
and increased cost of therapy.1,2 Recent systematic 
reviews3,4 and meta-analysis of observational studies5 
indicate that the rate of hospital admissions directly related 
to ADRs is between 3-5%. An ADR is defined by the 
Medicines and Healthcare Products Regulatory Agency 
(MHRA) as “an unwanted or harmful reaction experienced 
following the administration of a drug or a combination of 
drugs under normal conditions of use and which is 
expected to be related to the drug”.6 
Some ADRs are predictable when patients are prescribed 
the same medications to which they have previously 
experienced an ADR.7 The spontaneous and prompt 
reporting of ADRs is one of the important activities of 
pharmacovigilance and is fundamental in the post-
marketing surveillance of medicines that helps in ensuring 
medicine safety.8 Spontaneous reporting system (SRS) is 
the most commonly used system worldwide to report ADRs 
by health care professionals as well as patients themselves 
to the national authorities regulating pharmacovigilance 
activities.9 The United Kingdom (UK)’s Yellow Card Scheme, 
administered by the Medicines and Healthcare products 
Regulatory Agency (MHRA) was initially open for doctors 
and dentists only to report ADRs. In 1997, this scheme 
invited hospital pharmacists to report ADRs and two years 
later accepted community pharmacists as ADR reporters.10 
Community pharmacists in particular are well placed to 
identify and report ADRs, as they have direct interaction 
with the public11 who visit community pharmacists to 
obtain Over The Counter (OTC) and herbal medicines as 
well vitamins and other supplements. However, despite of 
this frequent interaction with the public, fewer ADRs are 
reported by community pharmacists compared to hospital 
pharmacists.
11
 This variation in ADR reporting could be 
explained by the fact that hospital pharmacists’ clinical 
background, access to medical records together with their 
frequent interaction with the prescribers allows them to 
develop better understanding about suspected ADRs and 
the ADR reporting system.12 However, community 
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pharmacists considered as the most accessible healthcare 
professional can effectively utilize this opportunity by 
making important contributions to the ADR reporting 
through early identification and reporting of suspected 
ADRs.  
Although, a lot of work has been done to explore the 
knowledge, perception and barriers towards ADR reporting 
by community pharmacists worldwide13-17, very little is 
known about the factors which are preventing community 
pharmacists in the UK from reporting an ADR.18,19 Some of 
the reasons for not reporting ADRs reported in previous 
studies in the UK included lack of time, lack of information 
about suspected ADRs and ADRs not considered serious 
enough to report. However, it is noteworthy to mention 
here both studies referenced above were conducted prior 
to the permission granted to community pharmacists by 
MHRA to report ADRs in the UK. Given the limited and out 
dated evidence on ADR reporting by community 
pharmacists in UK, there was a need to update the current 
evidence base. The current study, therefore aims to 
identify the barriers to ADR reporting among community 
pharmacists practicing in the UK. This will assist the 
stakeholders to intervene and facilitate the reporting of 
ADRs by community pharmacists. 
 
METHODS 
A cross sectional study was conducted from 1st April 2012 
to September 2012. Community pharmacists practising in 
the West Midlands, UK, were approached for participation 
in this study. 
Study development 
A questionnaire approach was used in this study. Both 
paper as well as online questionnaires were developed 
using the style and format of some of the questions 
(barriers to ADR reporting) used in a previous study.20 Since 
the previous questionnaire was designed for medical 
practitioners, the authors expected the barriers reported 
by community pharmacists to be different from those 
reported by the medical practitioners. Therefore, the study 
questionnaire included specific questions to identify the 
barriers of ADR reporting in community pharmacy. For 
example, the questionnaire included barriers such as lack of 
access to internet in the pharmacy, lack of complete 
information about ADR and lack of awareness about what 
to report and how to report. The authors removed barriers 
such as ADR process being too bureaucratic and concern 
that report could be used in a legal case for damages by the 
patient from the previous questionnaire as these questions 
were not considered to be relevant for this study. The 
questionnaire was piloted among a small number (n=30) of 
community pharmacists. The reliability and internal 
consistency of the questionnaire was assessed using 
Cronbach’s alpha. The alpha value for the study tool was 
found to be 0.78. In addition, factor analysis was performed 
using Bartlett’s test of sphericity and Kaiser-Mayer-Olkin 
measure of sampling adequacy. The Bartlett’s test of 
sphericity was found to be 0.0000 and Kaiser-Mayer-Olkin 
measure of sampling adequacy was found to be 0.840. 
According to Sheridan and Lyndall21, a measure of more 
than 0.6 reflects the adequacy of the contents of the 
questionnaire. 
Contents of study questionnaire 
The study questionnaire was comprised of 25 Items. 
Section one had six items that explored the demographic 
information of respondents and the number of ADRs 
reported by them. Section two was comprised of two main 
items that gathered information about the types of ADRs 
that would be most likely reported by pharmacists among 
children and adults. In addition, this section also collected 
in depth information about the nature and severity of ADRs 
reported by pharmacists in the past three months. 
Section three was aimed to assess the awareness and 
confidence of pharmacists to report an ADR. Four items 
were displayed in this section and a nominal scale (yes/no) 
was provided for the respondent’s convenience to disclose 
their response. Section four of the questionnaire was 
aimed to identify the barriers to ADR reporting process. 
This section was comprised of ten items and a nominal 
scale (yes/no) was used to document pharmacist 
responses. Section five was the last section of the study 
and comprised of three items that aimed to identify the 
facilitators to ADR reporting process. 
Inclusion and exclusion criteria 
The study included community pharmacists male or female, 
newly qualified or experienced working in the community 
pharmacies including large multiples, small multiples and 
independent pharmacies. The study did not include 
pharmacists working in hospitals, pharmaceutical industries 
or academia. 
Questionnaire distribution and data collection 
Pharmacists were invited to participate in the study by 
extending invitations to them individually by post and email 
as well as by giving a ten minutes long presentation at two 
local pharmacy committees meetings in the West Midlands 
area. Furthermore, management of the national 
Pharmaceutical Services Negotiating Committee were 
approached to request the distribution of online 
questionnaire to the local pharmacy committees. As a 
result two local pharmacy committees each in Dudley and 
Northampton posted the questionnaires on their relevant 
websites. In our further efforts to achieve the required 
number of participants, the local management of a large 
high street pharmacy chain in the UK was also approached 
to request the distribution of questionnaires. As a result, 
the management of the company agreed to distribute 
paper and online copies of questionnaires among their 
pharmacists based in the West Midlands area. 
Ethical issues 
Ethical approval was obtained from the central research 
and development office of the participating pharmacy 
chain. Furthermore, individual verbal consent was also 
obtained from the participants. The research protocol was 
in compliance with the University of Warwick research 
code of practice. The survey was completely anonymous as 
the researchers did not request any personal data from 
participants which could identify the participants. All 
information collected from this study was kept strictly 
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confidential. The procedures for handling, processing, 
storage and destruction of the data complied with the Data 
Protection Act 1998. Only members of the research team 
had access to the completed questionnaires. 
Statistical analysis 
A sample size of 145 was required based at the 5% level, 
95% Confidence Interval and keeping response distribution 
as 50%. This required us to recruit 230 pharmacists to 
compensate for any incomplete responses.  
For data analysis, Statistical Package for Social Sciences 
(SPSS) version 20 was used. The data was found to be not 
normally distributed due to the diversity in the professional 
experience, age of the participants and their position. 
Therefore, non-parametric tests were applied to estimate 
the association among the responses and demographic 
variables. Chi-Square test was applied to test the 
association between the demographics and barriers to 
ADRs reporting. However, in the case when cell count was 
less than 5 among less than 25% cell, fisher exact test was 
preferred. Furthermore, Binary regression was applied to 
identify the covariates for the barrier to ADRs reporting. All 
the binary responses were kept as dependent variables. 
Position, gender, age and no. of years qualified as a 
pharmacist (Job experience) were independent variables. 
Exp(B) at confidence interval of 95% was used to interpret 
the regression analysis. Overall, a significant value 0.05 was 
assigned for analysis. 
 
RESULTS  
Demographics of respondents 
Of the 230 invited community pharmacists, 138 
pharmacists responded (response rate 60%). Although, 
both paper and online copies of the questionnaire were 
distributed to the participants, all 138 participants who 
participated in the study completed paper based 
questionnaire. No online responses were received. The 
median age of respondents was 31 years. Most of the 
respondents were female 56% (n=77). Majority 43% (n=59) 
were store based pharmacists, followed 33.3% (n=46) relief 
pharmacists. Based on experience, 41% (n=56) of the 
pharmacists reported to have a 1-5 years of experience. 
Around 45% (n=62) of the pharmacists reported that had 
reported an ADR in the last three months. Details about the 
respondent’s demographics and number of ADRs reported 
are presented in Table 1. 
Types of ADRs likely to be reported by pharmacists 
Overall, it was reported that both serious and mild 
reactions from drugs with black triangle and ADRs 
associated with herbal drugs were the types of ADRs that 
would be most likely reported among children and adults 
(Table 2). Some of the ADRs reported by pharmacists 
included swelling of tongue suspected with gabapentin, 
severe cramps with rivaroxaban, severe myalgia with 
Table 1. Respondents and frequency of ADRs reported (N=138) 
Demographics N (%) 
Gender  
Male 61(44.2%) 
Female 77(55.8%) 
Age years) Mean SD  34 (10.57) 
Median [Range] 31 [23 – 65] 
23- 30 years 57 (41.30%) 
31- 40 years 32 (23.19%) 
41-50 years 20 (14.49%) 
51 and over 14 (10.14%) 
Position  
Pharmacy Manager 31(22.5%) 
Store Based Pharmacist 59 (42.8%) 
Relief Pharmacist 46 (33.3%) 
Not Disclosed 2 (1.4%) 
Job Experience  
<1 year 11 (8.0%) 
1-5 year 56 (40.6%) 
6-10 year 17 (12.3%) 
11-20 year 19 (13.8%) 
>20 years 33 (23.9%) 
Not disclosed 2(1.4%) 
Have you reported an ADR in the last 3 
months 
 
Yes 62(44.9%) 
No 55(39.9%) 
Not Disclosed 22 (15.9%) 
Number of ADRs reported in last 3 months  
1 ADR reported 28 (20.3%) 
2-5 ADR reported 26 (18.8%) 
6-10 ADR reported 3 (2.2%) 
>10 ADR reported 5 (3.6%) 
There were some missing values therefore the sum of 
responses will not be 100% 
Table 2: Types of ADRs likely to be reported among children and adults (N=138) 
Population Yes chi-square p –values 
Children    
Serious reaction from a POM 128(92.8%) 2.561 0.110 
Serious reaction from a herbal drug 111(80.4%) 3.823 0.148 
Serious reaction from an OTC medicine 120 (87.0%) 4.977 0.083 
Serious reaction from a drug with black triangle 132 (95.7%) 1.117 0.572 
Mild reaction from a drug with black triangle 105 (76.1) 8.049 0.018* 
Mild reaction from an existing drug 14 (10.1%) 1.804 0.406 
Other 2 (1.4%) 0.823 0.663 
Adults    
Serious reaction from a POM 132 (95.7%) 0.085 0.770 
Serious reaction from a herbal drug 114 (82.6%) 0.076 0.783 
Serious reaction from an OTC medicine 126 (91.3%) 0.179 0.672 
Serious reaction from a drug with black triangle 136 (98.6%) 1.608 0.205 
Mild reaction from a drug with black triangle 112 (81.2%) 3.878 0.038 
Mild reaction from an existing drug 53 (38.4%) 1.585 0.208 
Other 3 (2.2%) 0.147 0.702 
Association of age and position was non-significant; *significant; Ì= gender; Fischer exact test was applied. There were 
some missing values therefore the sum of responses will not be 100% 
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simvastatin, breathlessness with finasteride, fainting with 
ramipril, pruritus with dipyrimadole, severe allergy with 
tiotropium, severe urticaria with metformin and blotching 
with amlodipine. A severe ADR suspected from St. Johns 
Wart resulted in patient hospitalisation. 
Awareness about ADR reporting methods and confidence 
to report an ADR 
Overall, 94.9% (n=131) of the pharmacists were familiar 
with the paper based ADR reporting system. In addition, 
62.3% (n=86) of the pharmacists reported that they were 
familiar with the online reporting system. 72.5% (n=100) of 
the pharmacists were confident about how to report an 
ADR and of these, 62.3% (n=86) pharmacists were 
confident about which ADR to report (Table 3). Further 
analysis has reported that pharmacists from the age group 
of 51 and over [0.800, CI 0.190 – 3.370] are more likely to 
report an ADR in comparison to those from the age group ≤ 
50years. It was also reported that store based pharmacies 
were likely to be more confident about which ADR to 
report [0.680, 0.434 – 3.599]. In addition, age and 
experience of pharmacists were the other two factors that 
were reported to be associated with ADR reporting (Table 
4). 
Barriers to ADR reporting 
Lack of time 46.4% (n=64), and pharmacists perception that 
ADR is not serious enough to report (65.2%; n=90) were 
identified as barriers to ADR reporting. Reactions too well 
known to be reported 37.0% (n=51) was identified as 
another barrier to ADR reporting process (Table 5) 
Facilitators to ADR reporting 
Training and information about what to report 63.0% 
(n=87) and access to information technology to report 
61.6% (n=85) were identified as the two main facilitators to 
improve reporting of ADRs (Table 6). Further analysis 
reported that female pharmacists with less job experience 
strongly emphasised on the need for provision of 1) access 
to IT 0.859 [0.394 -1.872] and 2) information about how to 
report an ADR 0.845 [0.385 -1.855] to improve the 
reporting of ADRs (Table 7). 
 
DISCUSSION 
This study aimed to assess the understanding of community 
pharmacists about ADRs, their level of reporting and 
challenges to spontaneous reporting of ADRs. Majority of 
the pharmacists were reported to be more familiar with the 
paper based method than the online method of ADR 
reporting. About 72.5% of the pharmacists were confident 
to report an ADR. 
The study reported that just less than half of the 
pharmacists (45%) had reported one or more than one 
ADR. These results suggests a massive improvement in ADR 
reporting by the pharmacists in UK compared to the 
findings of two previous studies that reported 4%18 and 
21%19 respectively. Although this study reported an 
improvement in ADR reporting among community 
pharmacists, the average reporting by community 
pharmacists in the UK in general remains low and static. 
Approximately 370 ADR reports are submitted annually by 
community pharmacists that accounts for 3 to 4% of all 
direct health professional yellow card reporting in the UK.22 
ADRs should not be hard to find in the community where 
around 2% of GP consultations are due to ADRs.23 Other 
evidence suggests that up to 40% of patients in the primary 
care experience ADRs.24 Community pharmacists are in 
regular contact with patients and should therefore make 
full use of their unique position to contribute to the 
spontaneous reporting of ADRs. 
Table 3. Awareness about ADR reporting methods and confidence 
to report an ADR (N=138) 
Items.     N (%) Yes No 
Familiar with paper based ADR 
reporting 
131 (94.9%) 3 (2.1%) 
Familiar with online ADR reporting 86 (62.3%) 52 (37.7%) 
Confident how to report and ADR 100 (72.5%) 32 (23.2%) 
Confident which ADR to report 86 (62.3%) 47 (34.1%) 
There were some missing values therefore the sum of responses 
will not be 100% 
Table 4. Factors associated with the pharmacist s confidence about which ADR to report (N=138) 
Covariates df Exp(B) 
95% CI 
Lower Upper 
Position     
Pharmacy Manager(r) 1 1.000 - - 
Store Based Pharmacist  0.680 0.434 3.599 
Relief Pharmacist  0.581 0.540 3.001 
Gender 1 2.08 0.939 4.60 
Age     
23- 30 years 4 0.333 0.62 1.797 
31- 40 years  0.666 0.195 2.269 
41-50 years  0.486 0.123 1.919 
51 and over  0.800 0.190 3.370 
No. of year qualified as a pharmacist (Job experience)     
<1 year 4 0.342 0.063 1.841 
1-5 year  0.769 0.313 1.890 
6-10 year  0.839 0.249 2.829 
11-20 year  1.231 0.385 3.937 
>20 years (r)  1.335 0.441 4.120 
Binary logistic regression was applied, - cannot be estimated Dependant variable was Factors associated with the 
pharmacist confidence which ADR to report and independent variables were position, gender, age and No. of 
year qualified as a pharmacist (Job experience) 
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All pharmacists in this study reported that would report 
both serious and mild ADRs from drugs with black triangle 
among children as well as adults. Furthermore, more than 
90% would report serious reactions from POM. 87% of the 
community pharmacists would report ADRs suspected from 
OTC medicines and 82% of pharmacists would report ADRs 
suspected with herbal medicines. The study suggested that 
ADR reporting process is more likely to be influenced by the 
community pharmacists’ confidence to report an ADR. It 
was reported that pharmacists from the age group of 51 
and over are more likely to report an ADR in comparison to 
those less than 50 years. Moreover, greater job experience 
and type of practice were identified as the other two 
factors that were reported to be associated with ADR 
reporting.  
The study reported that community pharmacists’ 
consideration that ADR is not serious enough to report, 
followed by well-known ADRs and lack of time were the 
three main barriers to ADR reporting process. Such barriers 
or deterrents to reporting have not only been reported by 
community pharmacists in studies conducted in the UK18,19, 
but also in studies conducted outside the UK.25 The barriers 
identified in this study suggest the need to plan for further 
intervention based studies that aim to address some of 
these barriers and it also forms the basis of our future 
work. Our future work would aim to assess the impact of 
pharmacovigilance-based specific education on ADR 
reporting by community pharmacists by conducting a 
randomised controlled trial. 
The findings of this study underscore the importance of 
providing explicit education and training to improve the 
understanding and awareness of ADRs among community 
pharmacists. Previous studies aimed at investigating the 
extent of pharmacovigilance education provided to 
pharmacy students suggested an increased devotion to 
such education.26 A study in Denmark demonstrated the 
capabilities and competencies of trained pharmacy 
students in the identification and reporting of ADRs.27 
However, it will not be wise to generalise the findings of 
this particular study27 to practicing community pharmacists 
without extension of specific training and education to 
them.  
There is a need to nurture the culture of reporting along 
with the strengthening and re-enforcement of the 
pharmacovigilance education to community pharmacists. 
The general attitude towards reporting of adverse events is 
variable among various healthcare professionals.28-32 As far 
as community pharmacists are concerned, a previous study 
in UK reported that community pharmacists are unlikely to 
report an adverse event in the community pharmacy.32 This 
culture of reporting needs to change and will only be 
possible if all stakeholders including pharmacy professional 
bodies and pharmacy schools play a proactive role in 
promoting and fostering the culture of spontaneous 
reporting.  
This study has some key limitations. Although the barriers 
reported in this study are consistent with the barriers 
reported in previous studies, the study was conducted few 
years ago and therefore, some of the barriers reported in 
this study may not remain valid. The findings of this should 
therefore, be presented with caution. This study used an 
adopted questionnaire from an old study that was aimed to 
identify the barriers of medical practitioners towards ADR 
reporting. Since the study20 was designed for medical 
practitioners, the authors expected the barriers reported 
by community pharmacists to be different from the medical 
practitioners. Therefore, the study questionnaire included 
specific questions to identify the barriers of ADR reporting 
in community pharmacy. This adaptation was necessary to 
ensure the inclusion of questions that were suitable to 
address the research outcomes. The questionnaire relied 
on self-reported responses from the participants, therefore 
the actual number of pharmacists not reporting an ADR 
could be higher or vice versa.  
However, despite of the above mentioned limitations, this 
study has several strengths. The study achieved a response 
rate of 60% which was higher than the required sample 
size. Exclusion and inclusion criteria were rigorously applied 
to ensure that the study population was representative of 
the target population. The study achieved its objectives by 
identifying the barriers towards ADR reporting. 
Furthermore, the findings of this study have important 
implications for practice. Community pharmacists not only 
require encouragement to report ADRs but also need 
continuous professional educational programs with the aim 
of improving their knowledge and awareness about ADRs 
and its reporting. Furthermore, provision of access to 
patient medical records would allow community 
pharmacists to collect more information about the 
suspected drugs and would therefore help them in 
establishing the ADR causality. 
Table 5. Barriers to ADR reporting (N=138) 
Barriers to ADR reporting   N (%) Yes No Chi-square
 
Age (p-value) 
Not clear what ADR is 10 (7.2%) 128 (92.8%) 4.061 0.398 
Not clear how to report it 17 (12.3%) 121 (87.7%) 2.894 0.576 
Did not consider duty to report it - 136 (98.6%) - - 
Lack of time 64 (46.4%) 74 (53.6%) 3.644 0.456 
Lack of access to internet 23 (16.7%) 115 (83.3%) 12.192 0.016* 
Considered reaction to be too well known 51 (37.0%) 87 (63.0%) 15.466 0.004* 
Did not consider reaction serious enough to report 90 (65.2%) 48 (34.8%) 6.281 0.188 
Not sure which drugs were responsible 33 (23.9%) 105 (76.1%) 3.562 0.469 
Did not have complete information for making the report 37 (26.8%) 101 (73.2%) 1.507 0.825 
Other 11 (8.0%) 127 (92.0%) 0.317 0.989 
Gender and position have no significant association with the barriers to ADR reporting;  
Table 6. Support required improving the ADR 
reporting (N=138) 
Item N (%) 
Information about what to report  87 (63.00% 
Information about how to report  64 (46.40% 
IT access to report and ADR 85 (61.60% 
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CONCLUSIONS 
The current study reported an increasing trend of ADR 
reporting among community pharmacists practicing in the 
UK. Lack of time, reactions too well to be reported and 
ADRs considered not serious enough to report were 
identified as barriers to ADR reporting. Further training and 
education about the types of ADRs to be reported coupled 
with access to IT to the ADR reporting system will help to 
improve the reporting of ADRs. 
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